Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Micardis er større end risiciene ved behandling af essentiel hypertension hos voksne.
The Committee for Medicinal Products for Human Use (CHMP) decided that Micardis’ s benefits are greater than its risks for the treatment of essential hypertension in adults.